Overview

An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study

Status:
TERMINATED
Trial end date:
2025-04-25
Target enrollment:
Participant gender:
Summary
The primary objective of this open-label extension trial is to evaluate the long-term safety of AXS-05 for the treatment of Alzheimer's disease agitation in subjects that participated in ADVANCE-2 and ACCORD-2.
Phase:
PHASE3
Details
Lead Sponsor:
Axsome Therapeutics, Inc.